A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
A first-in-human trial from the Leibniz Institute for Immunotherapy found that a low-dose, stem cell memory–enriched CAR T-cell therapy achieved complete remission in some high-risk B-cell cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results